StockData
Cullinan Therapeutics, Inc. logo

Cullinan Therapeutics, Inc. (CGEM) stock

CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$9.50−0.78 (-7.59%)

Close on Nov 16, 2026Market cap $611.37MP/E –Yield –

Earnings

Cullinan Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 9, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.74
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Cullinan Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 9, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 10, 2026before the open––-$0.74Release
Q2 FY2026ended Jun 30, 2026Aug 6, 2026before the open–––Release
Q1 FY2026ended Mar 31, 2026May 7, 2026before the open––-$0.75Release
Q4 FY2025ended Dec 31, 2025Mar 10, 2026before the open––-$0.77Release
Q3 FY2025ended Sep 30, 2025Nov 6, 2025before the open–––Release
Q2 FY2025ended Jun 30, 2025Aug 7, 2025before the open––-$1.07Release
Q1 FY2025ended Mar 31, 2025May 8, 2025before the open–––Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025before the open––-$0.73Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024before the open––-$0.69Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024before the open––-$0.75Release
Q1 FY2024ended Mar 31, 2024May 15, 2024after the close––-$0.86Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Cullinan Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Cullinan Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Cullinan Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Update
  4. Update
  5. Update
  6. Update
  7. Update
  8. Results
  9. Update
  10. Update
  11. Update
  12. Results
  13. Results
  14. Results
  15. Update

See a number that looks wrong?